HOME Research Insight Expansion and Acquisition Were the Key Growth Strategies Adopted by Players in the Viral Clearance Market between 2012 and 2015



Expansion and Acquisition Were the Key Growth Strategies Adopted by Players in the Viral Clearance Market between 2012 and 2015


Major players in the viral clearance market include Avance Biosciences Inc. (U.S.), BSL BIOSERVICE (Germany), Clean Cells (France), Charles River Laboratories International, Inc. (U.S.), Lonza Group (Switzerland), Merck & Co., Inc. (U.S.), Sigma-Aldrich Corporation (U.S.), SGS S.A. (Switzerland), Texcell, Inc. (France), and WuXi PharmaTech (Cayman) Inc. (China).

There is a high degree of consolidation in the viral clearance market, with few large players dominating the market. High degree of consolidation is major barriers for new entrants in this market. Small and medium-sized players account for a small share of the market and their business interests remain concentrated in local markets across emerging geographies. Sigma–Aldrich Corporation (U.S.), Charles River Laboratories International Inc. (U.S.), Wuxi PharmaTech (Cayman) Inc. (China), and SGS SA (Switzerland) are the leaders in this market. The combined market share of these four companies, far exceed that of all other players. Overall, about 76% of the global viral clearance market will be dominated by these companies in 2014. Furthermore, acquisitions by market leaders in this field have strengthened their market positions and have served to further consolidate the market. Some important acquisitions in this market include the acquisitions of WIL Research (U.S.) in 2016, and acquisition of Oncotest GmbH (Germany), and Celsis International Ltd (U.S.) in 2012 by Charles River Laboratories International (U.S), and acquisition of BioReliance (U.S.) in 2012 by Sigma-Aldrich Corporation (U.S.), and Exprimo, NV (Belgium) and Vitrology Limited (U.K.) in 2012 by SGS SA (Switzerland), and acquisition of Sigma-Aldrich Corporation (U.S.) in 2014 by Merck KGaA (Germany), and acquisition of XenoBiotic Laboratories, Inc. (U.S.) in 2014 by WuXi PharmaTech (Cayman) Inc. (China)

Acquisition and expansions were the two most important growth strategies employed in this market. An analysis of market developments between 2012 and 2016 revealed that expansion was the most adopted growth strategy employed by the market leaders in this period. For instance, in October 2014, SGS Life Science Services completed the expansion of biologics testing facility in Glasgow, UK. The 500 square meter expansion, with a staff of 45 personnel will offer a full range of validated bioanalytical methods for testing of biologics, viral vaccines, and gene & cell therapies. Similarly, in May 2014, WuXi PharmaTech, Inc. established a new biologics biosafety testing facility in Suzhou, China. The 38,000 square feet facility houses laboratories and offices. It significantly expanded the company's viral clearance service capabilities. This strategy was adopted by Charles River Laboratories International, Inc. (U.S.), SGS SA (Switzerland), WuXi PharmaTech (Cayman) Inc. (China), Lonza Group (Switzerland), Sigma-Aldrich Corporation (U.S.), and Merck & Co., Inc. (U.S.).

The other important growth strategies were acquisition, implemented to gain immediate technological competency and widen geographic presence. For instance, in September 2014, Merck KGaA (Germany) completed the acquisition of Sigma-Aldrich Corporation. The deal was valued at $140 per share, valuing the company at approximately $17 billion. This acquisition expanded the company’s business in various geographies and enhanced its product portfolio. This strategy was adopted by Charles River Laboratories International, Inc. (U.S.), Sigma–Aldrich Corporation (U.S.), SGS SA (Switzerland), and Merck & Co., Inc. (U.S.).

Related Reports:

Viral Clearance Market by Application (Stem Cell, Blood, Tissue, Cell & Gene Therapy), Method (Inactivation, Removal (Precipitation), Detection (PCR, ELISA)) & End User (Pharmaceutical & Biotechnology, CROs, Research Institute) - Global Forecast to 2020

Contact:
Mr. Rohan
Markets and Markets
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune, Maharashtra 411013, India
1-888-600-6441
Email: sales@marketsandmarkets.com

Connect Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441

Search reports